

# CITATION REPORT

List of articles citing

**Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer**

**DOI: 10.1002/gcc.20366**

**Genes Chromosomes and Cancer, 2006, 45, 1033-40.**

**Source:** <https://exaly.com/paper-pdf/40855643/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
445	Regularized Multivariate Regression for Identifying Master Predictors with Application to Integrative Genomics Study of Breast Cancer. <b>2010</b> , 4, 53-77		82
444	International Agency for Research on Cancer workshop on 'Expression array analyses in breast cancer taxonomy'. <b>2006</b> , 8, 303		6
443	Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. <b>2006</b> , 10, 529-41		998
442	Integrated breast cancer genomics. <b>2006</b> , 10, 453-4		3
441	Demystifying basal-like breast carcinomas. <b>2007</b> , 60, 1328-32		41
440	The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. <b>2007</b> , 67, 10230-40		68
439	Flexible and accurate detection of genomic copy-number changes from aCGH. <b>2007</b> , 3, e122		39
438	Application of Genomics in Clinical Oncology. <b>2007</b> , 26, 79-93		1
437	Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. <b>2007</b> , 13, 7305-13		28
436	Integrated profiling of basal and luminal breast cancers. <b>2007</b> , 67, 11565-75		232
435	The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity. <b>2007</b> , 19, 552-7		40
434	A perspective on DNA microarrays in pathology research and practice. <b>2007</b> , 171, 375-85		42
433	Triple-negative breast cancer: therapeutic options. <b>2007</b> , 8, 235-44		664
432	Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. <b>2007</b> , 9, R59		53
431	High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. <b>2007</b> , 8, R215		230
430	Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. <b>2007</b> , 67, 8504-10		221
429	Cancer genomics: integrating form and function. <b>2007</b> , 28, 1387-92		14

428	Origins of breast cancer subtypes and therapeutic implications. <b>2007</b> , 4, 516-25		126
427	Cancer genome analysis: a landscape seen from many angles. <b>2007</b> , 4, 269-276		
426	Diagnostic significance of allelic imbalance in cancer. <b>2007</b> , 1, 159-68		1
425	[Towards an integrated cellular and molecular: definition of breast cancers]. <b>2007</b> , 23, 626-32		1
424	Targets of genome copy number reduction in primary breast cancers identified by integrative genomics. <i>Genes Chromosomes and Cancer</i> , <b>2007</b> , 46, 288-301	5	33
423	High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , <b>2007</b> , 46, 543-58	5	162
422	Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. <b>2007</b> , 110, 1687-96		73
421	Triple negative tumours: a critical review. <b>2008</b> , 52, 108-18		640
420	Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. <b>2007</b> , 87, 737-54		62
419	Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. <b>2007</b> , 20, 474-81		179
418	SIRAC: Supervised Identification of Regions of Aberration in aCGH datasets. <b>2007</b> , 8, 422		9
417	Chromosome alterations associated with positive and negative lymph node involvement in breast cancer. <b>2007</b> , 173, 114-21		7
416	Molecular profiling of breast cancer: transcriptomic studies and beyond. <b>2007</b> , 64, 3185-200		11
415	Molecular subtyping of breast cancer: opportunities for new therapeutic approaches. <b>2007</b> , 64, 3219-32		20
414	Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. <b>2008</b> , 15, 153-8		29
413	The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis. <b>2008</b> , 1, 42		95
412	Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. <b>2008</b> , 215, 398-410		116
411	Absence of ESR1 amplification in a series of breast cancers. <b>2008</b> , 123, 2970-2		23

410	Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability. <i>Genes Chromosomes and Cancer</i> , <b>2008</b> , 47, 71-83	5	13
409	Association of chromosome band 8q22 copy number gain with high grade invasive breast carcinomas by assessment of core needle biopsies. <i>Genes Chromosomes and Cancer</i> , <b>2008</b> , 47, 405-17	5	9
408	DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. <i>Genes Chromosomes and Cancer</i> , <b>2008</b> , 47, 490-9	5	79
407	High-resolution genomic and expression analyses of copy number alterations in breast tumors. <i>Genes Chromosomes and Cancer</i> , <b>2008</b> , 47, 530-42	5	123
406	Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. <i>Genes Chromosomes and Cancer</i> , <b>2008</b> , 47, 680-96	5	73
405	CGH microarrays and cancer. <b>2008</b> , 19, 36-40		91
404	Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. <b>2008</b> , 72, 1056-63		33
403	Molecular diagnosis in breast cancer. <b>2008</b> , 14, 202-213		8
402	Hereditary breast cancer: from molecular pathology to tailored therapies. <b>2008</b> , 61, 1073-82		35
401	Yes-associated protein (YAP) functions as a tumor suppressor in breast. <b>2008</b> , 15, 1752-9		236
400	Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. <b>2008</b> , 27, 3165-75		68
399	Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. <b>2008</b> , 27, 3635-40		168
398	ESR1 gene amplification in breast cancer: a common phenomenon?. <b>2008</b> , 40, 807-8; author reply 810-2		46
397	Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options. <b>2008</b> , 8 Suppl 4, S171-8		13
396	Array comparative genomic hybridization copy number profiling: a new tool for translational research in solid malignancies. <b>2008</b> , 18, 98-104		40
395	CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer. <b>2008</b> , 2, 327-39		45
394	Comparison of the Agilent, ROMA/NimbleGen and Illumina platforms for classification of copy number alterations in human breast tumors. <b>2008</b> , 9, 379		49
393	Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models. <b>2008</b> , 10, 213		19

392	[Array-CGH for routine diagnosis of cryptic chromosomal imbalances]. <b>2008</b> , 56, 368-74	3
391	What is triple-negative breast cancer?. <b>2008</b> , 44, 2799-805	230
390	Basal-like breast cancer: a critical review. <b>2008</b> , 26, 2568-81	657
389	Triple-negative breast cancer: risk factors to potential targets. <b>2008</b> , 14, 8010-8	336
388	An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. <b>2008</b> , 29, 1475-82	43
387	Breast Cancer. <b>2008</b> ,	3
386	The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. <b>2008</b> , 68, 8201-9	110
385	Comparative genomic hybridisation arrays: high-throughput tools to determine targeted therapy in breast cancer. <b>2008</b> , 75, 63-74	15
384	Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. <b>2008</b> , 36, e13	59
383	Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. <b>2008</b> , 4, e1000081	82
382	Impact of basal-like breast carcinoma determination for a more specific therapy. <b>2008</b> , 75, 95-103	25
381	Contributions of Microarray Analysis to Soft Tissue Tumor Diagnosis. <b>2008</b> , 13, 78-84	1
380	Triple negative breast cancer: current understanding of biology and treatment options. <b>2008</b> , 20, 40-6	50
379	Bibliography. Current world literature. Endocrine tumors and cancer biology. <b>2008</b> , 20, 122-43	
378	. <b>2009</b> ,	2
377	Tiling path genomic profiling of grade 3 invasive ductal breast cancers. <b>2009</b> , 15, 2711-22	138
376	Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. <b>2009</b> , 15, 441-51	265
375	The multifaceted role of MTDH/AEG-1 in cancer progression. <b>2009</b> , 15, 5615-20	215

374	A systems approach to analysis of molecular complexity in breast cancer. <b>2009</b> , 15, 417-9		15
373	Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. <b>2009</b> ,		2
372	Genomic characterization of esophageal squamous cell carcinoma from a high-risk population in China. <b>2009</b> , 69, 5908-17		46
371	Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma. <b>2009</b> , 33, 496-504		66
370	Pleomorphic lobular carcinoma of the breast: molecular pathology and clinical impact. <b>2009</b> , 5, 233-43		41
369	Introducing molecular subtyping of breast cancer into the clinic?. <b>2009</b> , 27, 1153-4		39
368	Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. <b>2009</b> , 20, 1639-46		216
367	High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. <b>2009</b> , 69, 663-71		119
366	Microalterations of inherently unstable genomic regions in rat mammary carcinomas as revealed by long oligonucleotide array-based comparative genomic hybridization. <b>2009</b> , 69, 5159-67		12
365	Clinical application of microarray-based molecular cytogenetics: an emerging new era of genomic medicine. <b>2009</b> , 155, 311-7		27
364	Genetic characterization of breast cancer and implications for clinical management. <b>2009</b> , 13, 4090-103		31
363	Therapeutic options for triple-negative breast cancers with defective homologous recombination. <b>2009</b> , 1796, 266-80		22
362	Chromosomal changes in aggressive breast cancers with basal-like features. <b>2009</b> , 193, 29-37		36
361	MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. <b>2009</b> , 15, 9-20		329
360	Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. <b>2009</b> , 16, 115-25		366
359	The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. <b>2009</b> , 124, 1552-64		82
358	Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. <i>Genes Chromosomes and Cancer</i> , <b>2009</b> , 48, 351-65	5	74
357	Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines. <i>Genes Chromosomes and Cancer</i> , <b>2009</b> , 48, 419-28	5	21

356	Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. <b>2009</b> , 117, 183-91	43
355	Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. <b>2009</b> , 116, 479-89	112
354	A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. <b>2009</b> , 118, 481-98	55
353	Patho-biological aspects of basal-like breast cancer. <b>2009</b> , 113, 411-22	61
352	Systems biology of breast cancer. <b>2009</b> , 1, 238-245	2
351	Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. <b>2009</b> , 218, 301-15	65
350	Complex landscapes of somatic rearrangement in human breast cancer genomes. <b>2009</b> , 462, 1005-10	684
349	Gene-expression signatures in breast cancer. <b>2009</b> , 360, 790-800	1095
348	The role of molecular analysis in breast cancer. <b>2009</b> , 41, 77-88	41
347	Integrative genomic approaches to understanding cancer. <b>2009</b> , 1790, 478-84	6
346	Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. <b>2009</b> , 3, 469-82	84
345	Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. <b>2009</b> , 11, R86	68
344	Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. <b>2009</b> , 11, R47	106
343	A decade of cancer gene profiling: from molecular portraits to molecular function. <b>2010</b> , 576, 61-87	9
342	Triple-negative breast cancer--current status and future directions. <b>2009</b> , 20, 1913-27	416
341	Molecular markers of breast axillary lymph node metastasis. <b>2009</b> , 9, 441-54	15
340	In vitro and in vivo analysis of B-Myb in basal-like breast cancer. <b>2009</b> , 28, 742-51	74
339	Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. <b>2009</b> , 10, 267-77	78

338	Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. <b>2009</b> , 45 Suppl 1, 11-26	50
337	Triple negative breast cancers: clinical and prognostic implications. <b>2009</b> , 45 Suppl 1, 27-40	173
336	Genomic profiling of prostate cancers from African American men. <b>2009</b> , 11, 305-12	32
335	Genetic alterations and oncogenic pathways associated with breast cancer subtypes. <b>2009</b> , 7, 511-22	171
334	Microarray-Based Comparative Genomic Hybridization. 135-161	
333	What is the difference between triple-negative and basal breast cancers?. <b>2010</b> , 16, 12-6	30
332	Regularized multivariate regression for identifying master predictors with application to integrative genomics study of breast cancer. <b>2010</b> , 4,	159
331	Profiling the cancer genome. <b>2010</b> , 11, 133-59	36
330	Clinicopathological features and treatment strategy for triple-negative breast cancer. <b>2010</b> , 15, 341-51	36
329	An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. <b>2010</b> , 121, 575-89	132
328	Subtypes of familial breast tumours revealed by expression and copy number profiling. <b>2010</b> , 123, 661-77	81
327	Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. <b>2010</b> , 121, 261-71	67
326	Regulatory T cells and breast cancer: implications for immunopathogenesis. <b>2010</b> , 29, 569-79	90
325	Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues. <b>2010</b> , 10, 15	28
324	Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. <b>2010</b> , 10, 604	104
323	BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. <b>2010</b> , 10, 654	46
322	Genomic distance entrained clustering and regression modelling highlights interacting genomic regions contributing to proliferation in breast cancer. <b>2010</b> , 4, 127	9
321	Prognostic and predictive value of 16p12.1 and 16q22.1 copy number changes in human breast cancer. <b>2010</b> , 198, 52-61	13



320	High-resolution genomic profiling to predict 10-year overall survival in node-negative breast cancer. <b>2010</b> , 198, 79-89		9
319	Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure. <i>Genes Chromosomes and Cancer</i> , <b>2010</b> , 49, 699-710	5	15
318	A prognostic DNA signature for T1T2 node-negative breast cancer patients. <i>Genes Chromosomes and Cancer</i> , <b>2010</b> , 49, 1125-34	5	49
317	Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells. <b>2010</b> , 222, 271-81		17
316	Breast cancer precursors revisited: molecular features and progression pathways. <b>2010</b> , 57, 171-92		232
315	Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. <b>2010</b> , 29, 1421-30		58
314	Phosphoinositide signalling in cancer: beyond PI3K and PTEN. <b>2010</b> , 10, 342-52		316
313	DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. <b>2010</b> , 16, 5796-804		26
312	Inferring tumor progression from genomic heterogeneity. <b>2010</b> , 20, 68-80		371
311	Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. <b>2010</b> , 8, 701-16		44
310	Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer. <b>2010</b> , 38, 88-95		13
309	A random coefficients model for regional co-expression associated with DNA copy number. <b>2010</b> , 9, Article25		7
308	Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients. <b>2010</b> , 16, 651-63		52
307	Allele-specific copy number analysis of tumors. <b>2010</b> , 107, 16910-5		699
306	Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer. <b>2010</b> , 28, 361-3		33
305	Identifying functional miRNA-mRNA regulatory modules with correspondence latent dirichlet allocation. <b>2010</b> , 26, 3105-11		76
304	Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. <b>2010</b> , 2, 38ra47		122
303	[Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas]. <b>2010</b> , 97, 357-63		6

302	Microarray-Based Gene Expression Profiling for Molecular Classification of Breast Cancer and Identification of New Targets for Therapy. <b>2010</b> , 41, 364-372	23
301	DNA amplifications in breast cancer: genotypic-phenotypic correlations. <b>2010</b> , 6, 967-84	18
300	Building networks with microarray data. <b>2010</b> , 620, 315-43	5
299	High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. <b>2010</b> , 12, R25	103
298	Tumors of the Breast. <b>2010</b> , 493-516	
297	Genomic instability in breast cancer: pathogenesis and clinical implications. <b>2010</b> , 4, 255-66	91
296	Triple-negative breast cancer: present challenges and new perspectives. <b>2010</b> , 4, 209-29	212
295	Tracing the tumor lineage. <b>2010</b> , 4, 267-83	96
294	DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. <b>2010</b> , 9, 68	109
293	Through a glass darkly: advances in understanding breast cancer biology, 2000-2010. <b>2010</b> , 10, 188-95	32
292	Future of personalized medicine in oncology: a systems biology approach. <b>2010</b> , 28, 2777-83	195
291	Breast cancer genomes--form and function. <b>2010</b> , 20, 4-14	43
290	Breast Cancer Biology and Clinical Characteristics. <b>2010</b> , 21-46	9
289	Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. <b>2010</b> , 12, R3	113
288	Synthetic lethal approaches to breast cancer therapy. <b>2010</b> , 7, 718-24	75
287	RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. <b>2010</b> , 12, R41	58
286	Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. <b>2010</b> , 12, R42	141
285	A pathway-based classification of human breast cancer. <b>2010</b> , 107, 6994-9	258

284	A method for finding novel associations between genome-wide copy number and dna methylation patterns. <b>2011</b> ,	
283	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. <b>2011</b> , 24, 157-67	447
282	DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. <b>2011</b> , 5, 77-92	97
281	Implications of genomic instability in the diagnosis and treatment of breast cancer. <b>2011</b> , 11, 445-53	26
280	Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3 $\sigma$ FOXM1, and a gene signature associated with mitosis. <b>2011</b> , 13, R70	64
279	Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression. <b>2011</b> , 13, R95	19
278	Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. <b>2011</b> , 13, R129	19
277	Array-based Comparative Genomic Hybridization and Its Application to Cancer Genomes and Human Genetics. <b>2011</b> , 10, 77	2
276	17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy. <b>2011</b> , 2, 799-804	3
275	The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. <b>2011</b> , 26, 352-9	26
274	Molecular profiling of triple negative breast cancer. <b>2010</b> , 32, 73-84	19
273	Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. <i>PLoS ONE</i> , <b>2011</b> , 6, e23543	3-7 36
272	Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast. <b>2011</b> , 59, 264-73	14
271	A new treasure in the breast cancer gene hunt. <b>2011</b> , 17, 422-3	14
270	Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology. <b>2011</b> , 130, 1-8	91
269	Allele-specific disparity in breast cancer. <b>2011</b> , 4, 85	1
268	Metastatic triple-negative breast cancer. <b>2011</b> , 23, 587-600	81
267	Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. <b>2011</b> , 128, 23-30	67

266	High-resolution analyses of gene copy number reveal new insights into the prognosis and progression of breast cancers. <b>2011</b> , 128, 41-3	
265	Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. <b>2011</b> , 127, 297-308	37
264	Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach. <b>2011</b> , 137, 795-809	22
263	Low-grade and high-grade invasive ductal carcinomas of the breast follow divergent routes of progression. <b>2011</b> , 8, 123-127	
262	Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. <b>2011</b> , 11, 42	145
261	The breast cancer genome--a key for better oncology. <b>2011</b> , 11, 501	6
260	Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. <b>2011</b> , 8, 11	79
259	Inferring causal genomic alterations in breast cancer using gene expression data. <b>2011</b> , 5, 121	46
258	Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. <i>Genes Chromosomes and Cancer</i> , <b>2011</b> , 50, 71-81	5 47
257	Quantitative structure-activity relationships for anticancer activity of 2-phenylindoles using mathematical molecular descriptors. <b>2011</b> , 7, 98-108	2
256	<sup>18</sup> F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. <b>2011</b> , 71, 5164-74	101
255	Astrocyte elevated gene-1 and breast cancer (Review). <b>2011</b> , 2, 399-405	11
254	Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. <b>2011</b> , 59, 615-29	93
253	Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival. <b>2011</b> , 4, 1609-16	15
252	Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. <b>2011</b> , 25, 199-211	118
251	To DNA or not to DNA? That is the question, when it comes to molecular subtyping for the clinic!. <b>2011</b> , 17, 4959-64	19
250	Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. <b>2011</b> , 22, 848-856	69
249	Exploratory factor analysis of pathway copy number data with an application towards the integration with gene expression data. <b>2011</b> , 18, 729-41	1

248	Basal phenotype breast cancer: implications for treatment and prognosis. <b>2011</b> , 7, 181-202	19
247	Systems biology and genomics of breast cancer. <b>2011</b> , 3,	127
246	The role of biomarkers in the development of novel cancer therapies. <b>2012</b> , 27, 89-99	1
245	FSR: feature set reduction for scalable and accurate multi-class cancer subtype classification based on copy number. <b>2012</b> , 28, 151-9	12
244	Molecular classification of estrogen receptor-positive/luminal breast cancers. <b>2012</b> , 19, 39-53	53
243	Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. <b>2012</b> , 109, 2778-83	154
242	Cancers du sein triples négatifs: Jusqu'où doit-on aller dans le bilan histologique?. <b>2012</b> , 565-570	
241	A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. <b>2012</b> , 106, 1107-16	35
240	Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. <b>2012</b> , 72, 5454-62	340
239	Cancer du sein. <b>2012</b> ,	
238	Major chromosomal breakpoint intervals in breast cancer co-localize with differentially methylated regions. <b>2012</b> , 2, 197	26
237	Phosphatases: the new brakes for cancer development?. <b>2012</b> , 2012, 659649	46
236	TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. <b>2012</b> , 30, 2615-23	359
235	Basal breast cancer: a complex and deadly molecular subtype. <i>Current Molecular Medicine</i> , <b>2012</b> , 12, 96-119	139
234	Integrated genomic analysis of breast cancers. <b>2012</b> , 15, 71-4	2
233	Relevance of PTEN loss in brain metastasis formation in breast cancer patients. <b>2012</b> , 14, R49	64
232	The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. <b>2012</b> , 14, R113	36
231	FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. <b>2012</b> , 14, R115	60

230	Germline copy number variants are not associated with globally acquired copy number changes in familial breast tumours. <b>2012</b> , 134, 1005-11		5
229	Genome-wide copy number analysis in primary breast cancer. <b>2012</b> , 16 Suppl 1, S31-5		19
228	Down-regulation of ANAPC13 and CLTCL1: Early Events in the Progression of Preinvasive Ductal Carcinoma of the Breast. <b>2012</b> , 5, 113-23		10
227	The consequences of chromosomal aneuploidy on the transcriptome of cancer cells. <b>2012</b> , 1819, 784-93		54
226	Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes. <b>2012</b> , 25, 185-96		44
225	SNP microarray analyses reveal copy number alterations and progressive genome reorganization during tumor development in SVT/t driven mice breast cancer. <b>2012</b> , 12, 380		6
224	An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis. <b>2012</b> , 5, 54		10
223	Comprehensive molecular portraits of human breast tumours. <b>2012</b> , 490, 61-70		8025
222	Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. <b>2012</b> , 181, 1807-22		88
221	Microarray Analysis Identifies an Expression Signature for Inflammatory Breast Cancer. <b>2012</b> , 243-258		
220	Neurofibromatosis Type 1. <b>2012</b> ,		16
219	Clinical Applications of Microarrays in Cancer. <b>2012</b> , 307-322		
218	Inflammatory Breast Cancer: An Update. <b>2012</b> ,		
217	Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases. <i>PLoS ONE</i> , <b>2012</b> , 7, e47537	3-7	15
216	Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer. <i>PLoS ONE</i> , <b>2012</b> , 7, e51719	3-7	12
215	Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. <b>2012</b> , 60, 9-21		75
214	BRACKing news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype. <b>2012</b> , 31, 131-42		9
213	High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers. <b>2012</b> , 19, 161-9		8

212	Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?. <b>2012</b> , 19, 206-11	9
211	The Diagnosis of Pleomorphic Lobular Carcinoma In Situ Warrants Complete Excision with Negative Margins. <b>2012</b> , 4, 96-101	3
210	Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. <b>2012</b> , 132, 379-89	41
209	Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. <b>2012</b> , 133, 865-80	87
208	Molecular insights on basal-like breast cancer. <b>2012</b> , 134, 21-30	64
207	A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer. <b>2012</b> , 60, 854-63	18
206	Genomic analysis: toward a new approach in breast cancer management. <b>2012</b> , 81, 207-23	20
205	Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. <b>2012</b> , 33, 763-76	40
204	Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. <b>2012</b> , 69, 223-45	51
203	Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b. <b>2012</b> , 131, 385-99	34
202	Dysfunctional telomeres promote genomic instability and metastasis in the absence of telomerase activity in oncogene induced mammary cancer. <b>2013</b> , 52, 103-17	8
201	Cancer Genomics. <b>2013</b> ,	4
200	A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. <b>2013</b> , 26, 1438-50	47
199	MicroRNA Cancer Regulation. <b>2013</b> ,	17
198	Pleiotropic roles of AEG-1/MTDH/LYRIC in breast cancer. <b>2013</b> , 120, 113-34	25
197	Drug resistance mediated by AEG-1/MTDH/LYRIC. <b>2013</b> , 120, 135-57	44
196	The complex genetic landscape of familial breast cancer. <b>2013</b> , 132, 845-63	94
195	Breast Cancer Metastasis and Drug Resistance. <b>2013</b> ,	5

194	Discovering functional microRNA-mRNA regulatory modules in heterogeneous data. <b>2013</b> , 774, 267-90	2
193	Breast Cancer Heterogeneity in Primary and Metastatic Disease. <b>2013</b> , 65-95	1
192	Triple-negative breast cancer and the need for new therapeutic targets. <b>2013</b> , 183, 1064-1074	110
191	p53 in the Clinics. <b>2013</b> ,	
190	CXCL12, CXCR4 and IFN $\gamma$ genes expression: implications for proinflammatory microenvironment of breast cancer. <b>2013</b> , 13, 211-9	19
189	Breast Cancer. <b>2013</b> , 707-713	
188	Cellular heterogeneity and molecular evolution in cancer. <b>2013</b> , 8, 277-302	340
187	Breast cancer biomarker measurements and standards. <b>2013</b> , 7, 17-29	30
186	Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance. <b>2013</b> , 182, 2048-57	21
185	Functional analysis-make or break for cancer predictability. <b>2013</b> , 743-744, 132-141	4
184	Nonfamilial breast cancer subtypes. <b>2013</b> , 973, 279-95	5
183	DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas. <b>2013</b> , 108, 1732-42	13
182	bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. <b>2013</b> , 2013, bas060	152
181	Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. <b>2013</b> , 2013, 915636	36
180	The gene desert mammary carcinoma susceptibility locus Mcs1a regulates Nr2f1 modifying mammary epithelial cell differentiation and proliferation. <b>2013</b> , 9, e1003549	17
179	Breast Cancer Genomics: From Portraits to Landscapes. <b>2013</b> , 255-294	
178	Triple-negative breast cancer: molecular characterization and targeted therapies. <b>2013</b> , 2, 417-430	1
177	Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. <b>2013</b> , 14, R126	65



176	The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer. <b>2013</b> , 5, 353-70		24
175	Gene Expression Meta-Analysis Identifies Cytokine Pathways and 5q Aberrations Involved in Metastasis of ERBB2 Amplified and Basal Breast Cancer. <b>2013</b> , 12, 203-19		2
174	Triple negative breast cancers have a reduced expression of DNA repair genes. <i>PLoS ONE</i> , <b>2013</b> , 8, e66243	3-7	27
173	Dual-color fluorescence in situ hybridization reveals an association of chromosome 8q22 but not 8p21 imbalance with high grade invasive breast carcinoma. <i>PLoS ONE</i> , <b>2013</b> , 8, e70790	3-7	9
172	Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. <i>PLoS ONE</i> , <b>2013</b> , 8, e64268	3-7	71
171	Serial Changes in Expression of Proteins in Response to Neoadjuvant Chemotherapy in Breast Cancer. <b>2013</b> ,		2
170	Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. <i>PLoS ONE</i> , <b>2014</b> , 9, e81843	3-7	42
169	Integrated analysis of copy number variation and genome-wide expression profiling in colorectal cancer tissues. <i>PLoS ONE</i> , <b>2014</b> , 9, e92553	3-7	35
168	Integration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition. <i>PLoS ONE</i> , <b>2014</b> , 9, e97681	3-7	46
167	Remodeling of the methylation landscape in breast cancer metastasis. <i>PLoS ONE</i> , <b>2014</b> , 9, e103896	3-7	25
166	Progenetix: 12 years of oncogenomic data curation. <b>2014</b> , 42, D1055-62		28
165	Standard of care and promising new agents for triple negative metastatic breast cancer. <b>2014</b> , 6, 2187-223		32
164	Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. <b>2014</b> , 20, 404-12		27
163	Basal-like breast cancer: update on clinicopathologic, immunohistochemical, and molecular features. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2014</b> , 138, 37-43	5	34
162	Omics Approaches in Breast Cancer. <b>2014</b> ,		8
161	Breast Cancer Genomics. <b>2014</b> , 53-103		
160	A sparse Ising model with covariates. <b>2014</b> , 70, 943-53		27
159	Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer. <b>2014</b> , 9, 367-79		11

158	Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine. <b>2014</b> , 2, 3		50
157	Association of novel gene polymorphisms RRM1 -756T>C and -269 C>A with breast cancer. <b>2014</b> , 28, 287-93		1
156	Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. <b>2014</b> , 32, 2794-803		197
155	Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer. <b>2014</b> , 23, 79-87		33
154	The omics of triple-negative breast cancers. <b>2014</b> , 60, 122-33		44
153	Primary relapse site pattern in women with triple-negative breast cancer. <b>2014</b> , 210, 571-5		10
152	Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors. <i>Genes Chromosomes and Cancer</i> , <b>2015</b> , 54, 235-48	5	6
151	An integrated approach to reveal miRNAs' impacts on the functional consequence of copy number alterations in cancer. <b>2015</b> , 5, 11567		5
150	Allelic imbalance at the HER2/TOP2A locus in breast cancer. <b>2015</b> , 10, 56		6
149	Genomic profiling of CHEK2*1100delC-mutated breast carcinomas. <b>2015</b> , 15, 877		30
148	Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential. <b>2015</b> , 9, 62		34
147	Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer. <b>2015</b> , e183-90		15
146	Genetic alterations in glioblastoma multiforme. 323-344		
145	Identification of Copy Number Aberrations in Breast Cancer Subtypes Using Persistence Topology. <b>2015</b> , 4, 339-69		12
144	Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling. <b>2015</b> , 2015, 746970		14
143	Breast cancer. 345-360		1
142	Personalized Therapies for Cancer Treatment. <b>2015</b> , 317-346		
141	Expression of polarity genes in human cancer. <b>2015</b> , 14, 15-28		15

140	Multiple genes identified as targets for 20q13.12-13.33 gain contributing to unfavorable clinical outcomes in patients with hepatocellular carcinoma. <b>2015</b> , 9, 438-46	17
139	Obesity and genomics: role of technology in unraveling the complex genetic architecture of obesity. <b>2015</b> , 134, 361-74	21
138	A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer. <b>2015</b> , 16, 225-32	17
137	Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguous. <b>2015</b> , 68, 362-7	15
136	Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes. <b>2015</b> , 9, 877-88	14
135	INPP4B and RAD50 have an interactive effect on survival after breast cancer. <b>2015</b> , 149, 363-71	8
134	Lymphovascular invasion and histologic grade are associated with specific genomic profiles in invasive carcinomas of the breast. <b>2015</b> , 36, 1835-48	19
133	Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. <b>2015</b> , 16, 436-46	175
132	Precision Molecular Pathology of Breast Cancer. <b>2015</b> ,	3
131	Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. <b>2015</b> , 152, 347-56	37
130	Molecular Classification of Breast Cancer. <b>2015</b> , 137-155	
129	Application of Chromosomal Microarray. <b>2015</b> , 181-217	
128	Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing. <b>2015</b> , 17, 102	23
127	Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. <b>2015</b> , 136, 204-11	48
126	Wip1 phosphatase in breast cancer. <b>2015</b> , 34, 4429-38	34
125	New generation of breast cancer clinical trials implementing molecular profiling. <b>2016</b> , 13, 226-35	3
124	Cat Mammary Tumors: Genetic Models for the Human Counterpart. <b>2016</b> , 3,	14
123	Chromosomal breakpoints in breast cancer co-localize with differentially methylated regions. 255-268	

122	Subtype-specific micro-RNA expression signatures in breast cancer progression. <b>2016</b> , 139, 1117-28	42
121	Over-expression of PTEN on proliferation and apoptosis in canine mammary tumors cells. <b>2016</b> , 20, 325-334	1
120	Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. <b>2016</b> , 21, 1063-78	35
119	Fully automatic classification of breast cancer microarray images. <b>2016</b> , 3, 348-359	3
118	Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods. <b>2016</b> , 18, 753-761	13
117	PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. <b>2016</b> , 22, 1303-1313	127
116	Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. <b>2016</b> , 8, 1-14	25
115	A systematic comparison of copy number alterations in four types of female cancer. <b>2016</b> , 16, 913	7
114	Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements. <b>2016</b> , 8, 1-8	14
113	An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells. <b>2016</b> , 18, 27	51
112	Personalised cancer care: promises and challenges of targeted therapy. <b>2016</b> , 109, 98-105	12
111	FOXO factors and breast cancer: outfoxing endocrine resistance. <b>2016</b> , 23, R113-30	34
110	Deregulated ALG-2/HEBP2 axis alters microtubule dynamics and mitotic spindle behavior to stimulate cancer development. <b>2017</b> , 232, 3067-3076	5
109	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. <b>2017</b> , 13, 914	44
108	Mutational Signatures in Breast Cancer: The Problem at the DNA Level. <b>2017</b> , 23, 2617-2629	73
107	Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. <b>2017</b> , 23, 4493-4500	12
106	Employing image processing techniques for cancer detection using microarray images. <b>2017</b> , 81, 139-147	14
105	PIM1: a promising target in patients with triple-negative breast cancer. <b>2017</b> , 34, 142	20

104	Copy number aberrations landscape of a breast tumor, connection with the efficiency of neoadjuvant chemotherapy. <b>2017,</b>	1
103	Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer. <b>2017, 77, 4673-4683</b>	21
102	Cancer Genomics. <b>2017, 43-63</b>	
101	Sparse multivariate factor analysis regression models and its applications to integrative genomics analysis. <b>2017, 41, 70-80</b>	5
100	Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity. <b>2017, 22, 193-211</b>	5
99	Homologous Recombination Deficiency in Breast Cancer: A Clinical Review.. <b>2017, 1, 1-13</b>	11
98	A genomic copy number signature predicts radiation exposure in post-Chernobyl breast cancer. <b>2018, 143, 1505-1515</b>	9
97	MicroRNA Networks in Breast Cancer Cells. <b>2018, 1711, 55-81</b>	13
96	Impact of Genomics on Personalization of Breast Cancer Care. <b>2018, 331-372</b>	1
95	Inferring Dysregulated Pathways of Driving Cancer Subtypes Through Multi-omics Integration. <b>2018, 101-112</b>	
94	Down-regulation of NAMPT expression by mir-206 reduces cell survival of breast cancer cells. <b>2018, 673, 149-158</b>	29
93	Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma. <b>2019, 9, 556</b>	10
92	Integrative Proteo-genomic Analysis to Construct CNA-protein Regulatory Map in Breast and Ovarian Tumors. <b>2019, 18, S66-S81</b>	2
91	The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression. <b>2019, 5, 22</b>	13
90	Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters. <b>2019, 11,</b>	34
89	Breast Cancer Metastasis and Drug Resistance. <b>2019,</b>	13
88	Breast Cancer Heterogeneity in Primary and Metastatic Disease. <b>2019, 1152, 75-104</b>	13
87	Metadherin enhances vulnerability of cancer cells to ferroptosis. <b>2019, 10, 682</b>	18

86	Insights into Impact of DNA Copy Number Alteration and Methylation on the Proteogenomic Landscape of Human Ovarian Cancer via a Multi-omics Integrative Analysis. <b>2019</b> , 18, S52-S65	15
85	Association Analysis of Deep Genomic Features Extracted by Denoising Autoencoders in Breast Cancer. <b>2019</b> , 11,	11
84	PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. <b>2019</b> , 8,	65
83	Multi-omics Analysis of Primary Cell Culture Models Reveals Genetic and Epigenetic Basis of Intratumoral Phenotypic Diversity. <b>2019</b> , 17, 576-589	6
82	ATM-dependent activation of SIM2s regulates homologous recombination and epithelial-mesenchymal transition. <b>2019</b> , 38, 2611-2626	10
81	KLP-PI: a new prognostic index for luminal B HER-2-negative breast cancer. <b>2019</b> , 32, 172-184	2
80	The Expression Analysis of Intestinal Cancer Stem Cell Marker Lgr5 in Colorectal Cancer Patients and the Correlation with Histopathological Markers. <b>2020</b> , 51, 591-599	3
79	MatchMixer: a cross-platform normalization method for gene expression data integration. <b>2020</b> , 36, 2486-2491	3
78	In silico pathway analysis based on chromosomal instability in breast cancer patients. <b>2020</b> , 13, 168	1
77	Genomic Signatures in Luminal Breast Cancer. <b>2020</b> , 15, 355-365	5
76	Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer. <b>2020</b> , 6, 40	5
75	Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors. <b>2020</b> , 10, 1415	8
74	High Levels of Chromosomal Copy Number Alterations and TP53 Mutations Correlate with Poor Outcome in Younger Breast Cancer Patients. <b>2020</b> , 190, 1643-1656	4
73	Magneto-Mediated Electrochemical Sensor for Simultaneous Analysis of Breast Cancer Exosomal Proteins. <b>2020</b> , 92, 5404-5410	45
72	Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions. <b>2020</b> , 6, 26	6
71	Analysis of Copy-Number Variations and Feline Mammary Carcinoma Survival. <b>2020</b> , 10, 1003	3
70	Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. <i>PLoS ONE</i> , <b>2020</b> , 15, e0231711	3-7 5
69	Pharmacogenetics of Breast Cancer. <b>2020</b> ,	

68	Tumor Suppressor Effect of RBMS3 in Breast Cancer. <b>2021</b> , 20, 15330338211004921	1
67	An mRNA expression-based signature for oncogene-induced replication-stress.	
66	DeePaN: deep patient graph convolutional network integrating clinico-genomic evidence to stratify lung cancers for immunotherapy. <b>2021</b> , 4, 14	9
65	Chaperonin-Containing TCP1 Complex (CCT) Promotes Breast Cancer Growth Through Correlations With Key Cell Cycle Regulators. <b>2021</b> , 11, 663877	4
64	Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment. <b>2021</b> , 13,	7
63	Stem cell therapy: A paradigm shift in breast cancer treatment. <b>2021</b> , 13, 841-860	1
62	Tumor elastography and its association with cell-free tumor DNA in the plasma of breast tumor patients: a pilot study. <b>2021</b> , 11, 3518-3534	0
61	Identification of putative actionable alterations in clinically relevant genes in breast cancer. <b>2021</b> , 125, 1270-1284	
60	Somatic Alterations and Implications in Breast Cancer. <b>2009</b> , 183-213	1
59	Assessing TP53 Status in Human Tumors: Lessons from Breast Cancer. <b>2013</b> , 147-165	1
58	Biology and Treatment of Basal-Like Breast Cancer. <b>2013</b> , 91-109	2
57	Genetic Alterations in Normal and Malignant Breast Tissue. <b>2010</b> , 53-66	1
56	Canine and Feline Spontaneous Mammary Tumours as Models of Human Breast Cancer. <b>2020</b> , 173-207	2
55	Pathology of BRCA Tumors. <b>2017</b> , 89-117	1
54	Systems Biology and Integrative Omics in Breast Cancer. <b>2014</b> , 333-352	2
53	The Molecular Evolution of Breast Cancer Precursors and Risk Indicators. <b>2011</b> , 89-117	3
52	Molecular Oncology of Breast Cancer. <b>2009</b> , 501-531	1
51	Triple-Negative and Basal-like Carcinoma. <b>2012</b> , 446-478	1

50	Breast Cancer. <b>2011</b> , 352-359		1
49	RCP is a human breast cancer-promoting gene with Ras-activating function. <b>2009</b> , 119, 2171-83		89
48	Breast cancer - one term, many entities?. <b>2011</b> , 121, 3789-96		152
47	An adaptable generalization of Hotelling's $T^2$ test in high dimension. <b>2020</b> , 48,		6
46	Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. <i>PLoS ONE</i> , <b>2009</b> , 4, e4710	3-7	74
45	Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. <i>PLoS ONE</i> , <b>2009</b> , 4, e6146	3-7	537
44	8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. <i>PLoS ONE</i> , <b>2009</b> , 4, e7239	3-7	64
43	High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. <i>PLoS ONE</i> , <b>2011</b> , 6, e16950	3-7	50
42	arrayMap: a reference resource for genomic copy number imbalances in human malignancies. <i>PLoS ONE</i> , <b>2012</b> , 7, e36944	3-7	27
41	Expression and function of the protein tyrosine phosphatase receptor J (PTPRJ) in normal mammary epithelial cells and breast tumors. <i>PLoS ONE</i> , <b>2012</b> , 7, e40742	3-7	14
40	Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data. <i>PLoS ONE</i> , <b>2013</b> , 8, e53014	3-7	41
39	Concurrent gene signatures for han chinese breast cancers. <i>PLoS ONE</i> , <b>2013</b> , 8, e76421	3-7	40
38	Long non-coding RNAs differentially expressed between normal versus primary breast tumor tissues disclose converse changes to breast cancer-related protein-coding genes. <i>PLoS ONE</i> , <b>2014</b> , 9, e106076	3-7	29
37	Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126371	3-7	18
36	Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers. <i>PLoS ONE</i> , <b>2016</b> , 11, e0158259	3-7	12
35	Integrated landscape of copy number variation and RNA expression associated with nodal metastasis in invasive ductal breast carcinoma. <i>Oncotarget</i> , <b>2018</b> , 9, 36836-36848	3-3	7
34	Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy. <i>Oncotarget</i> , <b>2015</b> , 6, 43135-43	3-3	25
33	Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing. <i>Oncotarget</i> , <b>2015</b> , 6, 37169-84	3-3	19



32	Breast Cancer Targeted Treatment Strategies: Promising Nanocarrier Approaches. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2020</b> , 20, 1300-1310	2.2	2
31	Basal-like breast carcinoma: from expression profiling to routine practice. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2009</b> , 133, 860-8	5	58
30	Use of Single-Nucleotide Polymorphism Array for Tumor Aberrations in Gene Copy Numbers. <b>2008</b> , 75-88		
29	Cancer Genes, Genomes, and the Environment. <b>2009</b> , 808-817		
28	Learning Network from High-Dimensional Array Data. <i>Computational Biology</i> , <b>2010</b> , 133-156	0.7	
27	Abstract PL1-1: Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. <b>2010</b> ,		
26	Somatic Copy Number Alterations: Gene and Protein Expression Correlates in NF1-Associated Malignant Peripheral Nerve Sheath Tumors. <b>2012</b> , 405-428		
25	Molecular Testing in Breast Cancer. <b>2014</b> , 169-188		
24	Tumors of the breast. 426-446		
23	Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer.		
22	Molecular Pathway and Fluorescence In Situ Hybridization Testing of ERBB2 (HER2) Gene Amplification in Invasive Ductal Carcinoma of Breast. <b>2019</b> , 237-268		
21	Amplification of genomic regions harbouring genes with dose-limiting effects provides selection pressure for acquiring aberrant epigenetic silencing in ovarian cancer.		
20	DeePaN: A deep patient graph convolutional network integrating clinico-genomic evidence to stratify lung cancers benefiting from immunotherapy.		1
19	Contribution of Stemness-linked Transcription Regulators to the Progression of Breast Cancer. <i>Current Molecular Medicine</i> , <b>2021</b> ,	2.5	
18	Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis.. <i>Nature Communications</i> , <b>2022</b> , 13, 791	17.4	2
17	Early Breast Cancer Evolution by Autosomal Broad Copy Number Alterations.. <i>International Journal of Genomics</i> , <b>2022</b> , 2022, 9332922	2.5	0
16	The extended concurrent genes signature for disease-free survival in breast cancer.. <i>Journal of the Formosan Medical Association</i> , <b>2022</b> ,	3.2	0
15	Image_1.TIF. <b>2020</b> ,		

14 Table\_1.xlsx. **2020**,

13 Image\_1.TIF. **2019**,

12 Image\_2.TIF. **2019**,

11 Image\_3.TIF. **2019**,

10 Image\_4.TIF. **2019**,

9 Image\_5.TIF. **2019**,

8 Image\_6.TIF. **2019**,

7 Image\_7.TIF. **2019**,

6 Table\_1.XLSX. **2019**,

5 : A copy number clustering tool designed to refit and recalibrate the baseline region of tumors□ profiles. *Computational and Structural Biotechnology Journal*, **2022**, 20, 3718-3728 6.8

4 Comparative Analysis of Gene Correlation Networks of Breast Cancer Patients Based on Mutations in TP53. *Biomolecules*, **2022**, 12, 979 5.9

3 A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. *Nature Communications*, **2022**, 13, 17.4 1

2 Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC). 0

1 XAI-CNVMarker: Explainable AI-based copy number variant biomarker discovery for breast cancer subtypes. **2023**, 84, 104979 0